Taurine → 2-(4-(3-(1-(4-(2,3-Dimethylphenoxy)butanoyl)-1,2,3,4-tetrahydroquinolin-5-yl)benzylcarbamoyl)piperazin-1-yl)ethanesulfonic acid

Participants

Reaction Steps

Example 118 was prepared using a procedure analogous to Example 115 except that 1-(5-(2-(3-aminobenzyl)-2H-tetrazol-5-yl)-3,4-dihydroquinolin-1(2H)-yl)-4-(2,3-dimethylphenoxy)butan-1-one was replaced with 1-(5-(3-(aminomethyl)phenyl)-3,4-dihydroquinolin-1(2H)-yl)-4-(2,3-dimethylphenoxy)butan-1-one and taurine was replaced with 2-(piperazin-1-yl)ethanesulfonic acid. LCMS, [M+H]+=649.3. 1H NMR (400 MHz, MeOD) δ 7.48-7.30 (m, 4H), 7.28-7.17 (m, 2H), 7.13-7.00 (m, 2H), 6.79 (d, J=7.5 Hz, 1H), 6.75 (d, J=8.2 Hz, 1H), 4.48 (s, 2H), 4.28 (br. s, 2H), 3.99 (t, J=5.2 Hz, 2H), 3.83 (t, J=7.0 Hz, 2H), 3.72 (br. s, 2H), 3.62 (t, J=6.9 Hz, 2H), 3.43-3.38 (m, 2H), 3.29 (t, J=6.9 Hz, 2H), 3.20 (br. s, 2H), 2.89 (t, J=7.0 Hz, 2H), 2.49 (t, J=6.1 Hz, 2H), 2.31-2.15 (m, 5H), 1.94 (s, 3H), 1.90-1.80 (m, 2H). HPLC-1: Rt=10.5 min, purity=99.3%; HPLC-2: Rt=10.4 min, purity=100%.

Provenance & Evidence